A recent review in this Journal, which criticizes NCCN’s recommendations based, in part, on the RTOG 9501 and the EORTC 22931 trials, warrants comment. We herein provide additional data addressing many of the points and misinterpretations raised in that review which convincingly supports the use of concomitant chemotherapy and radiotherapy in patients with good performance status and high-risk pathologic features after surgery for mucosal head and neck squamous cell carcinoma.